All In Biotech

Drug Trial Radar · NCT02924727

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an Acute Myocardial Infarction (AMI)

Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,669 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,669

Actual

Start

Dec 9, 2016

Primary completion

Feb 26, 2021

Study completion Feb 26, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.

Conditions

  • Acute Myocardial Infarction

Interventions

  • LCZ696 (sacubitril/valsartan)Drug

    LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively

  • RamiprilDrug

    Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules

  • Placebo of LCZ696Drug

    Matching placebo of LCZ696 tablets

  • Placebo of ramiprilDrug

    Matching placebo of ramipril capsule

  • ValsartanDrug

    Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization

  • Placebo of valsartanDrug

    matching placebo of valsartan for one day to patients who will be randomized to received ramipril

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With First CEC (Clinical Endpoint Committee) Confirmed Primary Composite EndpointTime frame: From randomization to first occurrence (up to approximately 43 months)

Locations

486 sites in 41 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Huntsville, Alabama

  • Novartis Investigative Site

    Gilbert, Arizona

  • Novartis Investigative Site

    Bakersfield, California

  • Novartis Investigative Site

    Carmichael, California

  • Novartis Investigative Site

    Los Alamitos, California

  • Novartis Investigative Site

    Northridge, California

  • Novartis Investigative Site

    Orange, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    Sylmar, California

  • Novartis Investigative Site

    Brandon, Florida

  • Novartis Investigative Site

    Hollywood, Florida

  • Novartis Investigative Site

    Jacksonville Beach, Florida

  • Novartis Investigative Site

    Ocala, Florida

  • Novartis Investigative Site

    Cumming, Georgia

  • Novartis Investigative Site

    Johns Creek, Georgia

  • Novartis Investigative Site

    Thomasville, Georgia

  • Novartis Investigative Site

    Boise, Idaho

  • Novartis Investigative Site

    Coeur d'Alene, Idaho

  • Novartis Investigative Site

    Muncie, Indiana

  • Novartis Investigative Site

    Munster, Indiana

  • Novartis Investigative Site

    Richmond, Indiana

  • Novartis Investigative Site

    Iowa City, Iowa

  • Novartis Investigative Site

    Alexandria, Louisiana

  • Novartis Investigative Site

    Baton Rouge, Louisiana

  • Novartis Investigative Site

    Covington, Louisiana

  • Novartis Investigative Site

    Hammond, Louisiana

  • Novartis Investigative Site

    Slidell, Louisiana

  • Novartis Investigative Site

    Bangor, Maine

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Rockville, Maryland

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    Kalamazoo, Michigan

  • Novartis Investigative Site

    Lansing, Michigan

  • Novartis Investigative Site

    Petoskey, Michigan

  • Novartis Investigative Site

    Saginaw, Michigan

  • Novartis Investigative Site

    Southfield, Michigan

  • Novartis Investigative Site

    Duluth, Minnesota

Showing 40 of 486 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.